Cyrcadia, Inc. Collaborates With the Canary Foundation for Early Breast Cancer Research

Share Article

Focus on Wearable Devices to Improve Early Cancer Detection Screening

Working together on early biomarker identification for multiple states of cancer will be of significant benefit to our research.

Cyrcadia Health and the Canary Foundation announced their intention to enter into collaborative research on improved early cancer detection screening through the use of Cyrcadia’s wearable devices. Through funding support from the Canary Foundation, Cyrcadia has established a multi-site trial, beginning at a leading Bay Area cancer hospital with near term expansion to the Stefanie Spielman Comprehensive Breast Foundation at The Ohio State University. This research will involve a 173 patient study focused on early breast cancer health screening.

“We are excited that the Canary Foundation has taken an interest in our personalized health screening technology,” said Rob Royea, president of Cyrcadia, Inc.    “The potential of collaboration with the only foundation in the world, which over the past 10 years has focused solely on early cancer detection, is highly prestigious. Working together on early biomarker identification for multiple states of cancer will be of significant benefit to our research. Our ability to correlate our findings with those biomarkers which are early indicators of breast cancer infusion is invaluable and could lead to additional applications for our wearable products.”

One in eight women in the U.S. alone are diagnosed with breast cancer annually. Approximately 500,000 die worldwide from the disease each year, many due to lack of early detection.

The company’s wearable, smartphone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect from two to 12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change. The results are transferred through a smart device to a global cancer library, where advanced analytical analysis occurs, and results are communicated back to the patient and physician.

“We are targeting both the 70 percent of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, as well as mass screening of patients with dense breasts,” said Royea. “Patients with dense breast tissue have a higher propensity for cancer. Furthermore, mammography is challenged by detecting cancer in dense breast tissue as it can mask cancer cells and lesions.”

The addition of the Canary Foundation to the research underway is intended to better risk stratify those patients with breast cancer earlier in the diagnostic process.

“We look forward to establishing this clinical relationship with Cyrcadia,” said Don Listwin, founder of the Canary Foundation. “There is a need to improve risk stratification for early breast cancer screening. For instance, women with dense breast tissue have a higher propensity for cancer. Limitations of current imaging standards inhibit the ability to detect cancer early in this population.

“Cyrcadia’s tissue-agnostic, screening technology could provide a much earlier alert to the state of cancer. We look forward to comparing our known biomarkers with the Cyrcadia patient population to determine the early screening value for this technology,” Listwin concluded.

About Cyrcadia, Inc.

Cyrcadia, Inc., also known as Cyrcadia Health, was founded as First Warning Systems in 2008, is based in Reno, Nev. The company’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia is underway in a final, limited clinical trial and a 510k device classification to validate the fourth generation of the product. Cyrcadia technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO)The company is preparing to apply for FDA Clearance and a Euro CE Mark to market in the European Union and Asia Pacific markets, with anticipation of launching its technology to market in 2016. Cisco Systems, Inc. is financially supporting the filming of a documentary by Ironbound Films called “Detected Movie” to be released about the evolution of Cyrcadia technology. Please visit http://www.DetectedMovie.com and Cyrcadia Health at http://www.cyrcadiahealth.com.

About Canary Foundation
Canary Foundation is a non-profit organization dedicated to the goal of identifying cancer early through a simple blood test, and then isolating it with imaging. Canary Foundation is based in Palo Alto, California and was founded by Don Listwin in 2004. The program areas of the foundation are early detection for ovarian, prostate, breast, lung, and pancreatic cancer.

For more information, please visit http://www.canaryfoundation.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laurie Hallwyler
ckj Communications
+1 650-248-9081
Email >

Laurie Hallwyler